Do large scale studies of the use of antipsychotics help us choose the most effective treatments for schizophrenia?

Author/s
Mark Agius, Jesus Perez
Citation
Issue 1 Summer 2011
CEPiP.2011.1.69-73
Abstract

A number of large-scale antipsychotic studies have been carried out in recent years. Before the introduction of atypical antipsychotics, all antipsychotics were considered to act on the D2 receptor and all appeared to have equal efficacy. The new generation of antipsychotics all act on multiple receptors and each has a different receptor profile, hence there have been many queries about which of these medications is most effective for the treatment of schizophrenia. The large scale studies were intended to compare the first generation antipsychotics to each of the second generation [or atypical] ones, thus enabling decisions to be made as to which were the most effective. This article reviews these studies and assesses the utility of their conclusions.

Keywords: antipsychotics, effectiveness, efficacy, recovery, schizophrenia, first episode psychosis

Cite as: Cutting Edge Psychiatry in Practice 2011, 1(1):69-73; https://doi.org/10.65031/rvyr8784

References

  1. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst; KP, Murray RM, Markwick A & Lewis SW: Randomized controlled trial of the effect on Quality of Life of second- vs; first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia; Study (CUtLASS 1). Arch Gen Psychiatry. 2006; 63:1079-87 https://doi.org/10.1001/archpsyc.63.10.1079
  2. Davies LM, Barnes TR, Jones PB, Lewis S, Gaughran F, Hayhurst K, Markwick A, Lloyd H; CUTLASS Team.A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. Value Health. 2008 ;11:549-62. https://doi.org/10.1111/j.1524-4733.2007.00280.x
  3. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck; RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz; BD, Severe J & Hsiao JK: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 22;353:1209-23. https://doi.org/10.1056/nejmoa051688
  4. Meyer JM et al Impact of Antipsychotic Treatment on Nonfasting Triglycerides in the CATIE Schizophrenia Trial Phase 1 Schizophr Res. 2008 August ; 103(1-3): 104–109 https://doi.org/10.1016/j.schres.2008.04.023
  5. Gasquet I, Haro JM, Tcherny-Lessenot S, Chartier F & Lépine JP: Remission in the outpatient care of schizophrenia: 3-year results from the Schizophrenia Outpatients Health Outcomes (SOHO) study in France. Eur Psychiatry. 2008; 23:491-6. https://doi.org/10.1016/j.eurpsy.2008.03.012
  6. Suarez D & Haro JM: Overview of the findings from the European SOHO study Expert Rev Neurother. 2008; 8:873-80. https://doi.org/10.1586/14737175.8.6.873
  7. Novick D, Haro JM, Suarez D, Vieta E & Naber D: Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res. 2009; 108:223-30. https://doi.org/10.1016/j.schres.2008.11.007
  8. Haro JM, Novick D, Suarez D & Roca M: Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study. J Psychiatr Res. 2009; 43:265-73. https://doi.org/10.1016/j.jpsychires.2008.06.001
  9. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P & Strakowski SD: Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164:1050-60. https://doi.org/10.1176/ajp.2007.164.7.1050
  10. Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM & Lieberman JA: Comparison of Atypicals in First Episode study group Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible dose, multicenter study. J Clin Psychiatry. 2008; 69:106-13. https://doi.org/10.4088/jcp.v69n0114
  11. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher- Rössler A & Grobbee DE; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008 ;371(9618):1085-97. https://doi.org/10.1016/s0140-6736(08)60486-9
  12. Agius M, Davis A, Gilhooley M, Chapman S, Zaman R: What do large scale studies of medication in schizophrenia add to our management strategies? Psychiatria Danubina 2010; 22 : 323–328 https://doi.org/10.1016/s0924-977x(09)70778-3
  13. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010; 123:225-33 https://doi.org/10.1016/j.schres.2010.07.012
  14. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009 ;166:152-63 https://doi.org/10.1176/appi.ajp.2008.08030368
  15. IRIS Guidelines 2000  
  16. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003 ;60:553-64 https://doi.org/10.1001/archpsyc.60.6.553
  17. Leucht S, Corves C, Arbter D, Engel R, Li C, Davis J. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis, Lancet 2009; 373: 31–41 https://doi.org/10.1016/s0140-6736(08)61764-x
  18. NICE Guidelines on Schizophrenia 2009.